The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | MRD in multiple myeloma: determining response
Rafael Fonseca
• 1 Jun 2018
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the importance of measurable residual disease (MRD). Dr Fonseca describes the results of a study that found that patients with multiple myeloma (MM) who were MRD-positive had a similar outcome regardless of the type of response observed.
